Prognostic value of systolic blood pressure increase and its correction in Ukrainian patients with arterial hypertension: the results of cohort study СИСТЕМА-2 (Systema-2)

Main Article Content

V. I. Tseluyko


The aim – to assess the effect of the systolic blood pressure lowering (SBP) on the decreasing of cardiovascular and cardiocerebral complications in 3 and 12 months after the therapy change in patients aged over 55 years without blood pressure control at the routine GP management.
Materials and methods. 102 physicians from various regions of Ukraine took part in СИСТЕМА-2 (Systema-2) study. The study consistently involved patients over the age of 55 who had applied to a GP with an arterial hypertension (a total of 2,040 patients).
Results and discussion. Among patients who took antihypertensive drugs (91.6 %), the mean SBP was 167 mm Hg, and the blood pressure target level was observed only in 6.9 % of the cases. After 3 months of treatment mean SBP was 138.0±1.0 mm Hg in group with the combination of indapamide with amlodipine and in group with other antihypertensive treatment – 151.0±4.8 mm Hg. After the one year of observation the most of patients reached the target level of SBP – mean SBP in patients taking the combination of indapamide with amlodipine was 132.0±0.5 mm Hg and other antihypertensive therapy – 136.0±1.4 mm Hg (42 % of patients took 3 and more antihypertensive medicines) (p=0,01). The unfavorable course of hypertension was not associated with the initial level of SBP, but the with level of SBP after 3 months of treatment. The number of non-fatal stroke in the group of patients taking the combination of indapamide with amlodipine was 0.4 %, in the group with other treatment was 1.9 %. Within a year 38 (2 %) patients died. The leading cause of death was cardiovascular diseases – 21 (55 %) patients.
Conclusions. Reduction of SBP was significantly higher in the group of patients taking the combination of amlodipine and indapamide after 3 and 12 months. The factor associated with a decrease in the incidence of stroke is the early achievement of the target level of SBP, as evidenced by statistically significant differences in this indicator in patients with stroke and in patients without this complication 3 months after their involvement in the study. The use of the recommended combination therapy for calcium antagonist and diuretic in patients aged over 55 years provides better control of blood pressure and statistically significant decreases in the number of strokes, even in the presence of other factors of an adverse prognosis. Low attachment and withdrawal therapy are associated with a significant deterioration in the prognosis.

Article Details


arterial hypertension, cohort study, systolic blood pressure, antihypertensive drugs, diuretics, calcium antagonists, combined therapy, stroke, cardiovascular death.


Data from the Center of Medical Statistics of the Ministry of Health in Ukraine 2017.

Guideline and clinical protocol of medical care providing “Arterial hypertension”. Order of the Ministry of Health in Ukraine № 384. 24.05.2012.

Tseluiko VI. The Realities of the treatment of arterial hypertension in Ukraine: results of cohort study SYSTEM-2. Ukrainskyi kardiolohichnyi zhurnal [Ukrainian Journal of Cardiology]. 2018;1:13–20 (in Russ)

Bavishi C, Goel S, Messerli F. Isolated Systolic Hypertension: An Update After SPRINT. The American Journal of Medicine. 2016;129(12):1251–1258.

Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen R, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt . Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008;358(18):1887–1898.

Dominiczak A., Asmar R. Systolic blood pressure-lowering efficacy and tolerability of IndapamideSR/Amlodipine vs Valsartan/ Amlodipine in hypertensive patients. Journal of Hypertension. 2016;34(e273).

Ettehad D, Emdin C, Kiran A, Anderson S, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022):957–967.

Hanon O, Boully C, Caillard L, Labourée F, Cochiello S, Chaussade E. Treatment of hypertensive patients with diabetes and microalbuminuria with combination indapamide SR/amlodipine: Retrospective analysis of NESTOR. American Journal of Hypertension. 2015;28(8):1064–1071.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, Backer G, Dominiczak A, Galderisi M, Grobbee D, Jaarsma T, Kirchhof P, Kjeldsen S, Laurent S, Manolis A, Nilsson P, Ruilope L, Schmieder R, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2013;31(7):1281–1357

McCormack T, Krause T, O’Flynn N. Management of hypertension in adults in primary care: NICE guideline. British Journal of General Practice. 2012;62(596):163–164.

Meschia J, Bushnell C, Boden-Albala B, Braun L, Bravata DM., Chaturvedi S, Creager MA, Eckel RH, Elkind M, Fornage M, Goldstein LB, Greenberg SM, Horvath SE, Iadecola C, Jauch EC, Moore WS, Wilson JA. Guidelines for the primary prevention of stroke. Stroke. 2014;45(12):3754–3832.

Rajsic S, Gothe H, Borba HH, Sroczynski G, Vujicic J, Toell T, Siebert U. Economic burden of stroke: a systematic review on post-stroke care. The European Journal of Health Economics. 2019;20(1):107–134.

Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. The Journal of Clinical Hypertension. 2015; 17(3):193–199.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. Journal of Hypertension. 2014;32(12):2285–2295.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. Journal of Hypertension. 2015;32(12):1321–1341

Wang J-G, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension. 2007;50(1):181–188.

Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet J-C, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. Journal of Hypertension. 2013;32(1):3–15.

Weir MR, Zappe D, Orloski LA, Sowers JR. How early should blood pressure control be achieved for optimal cardiovascular outcomes? Journal of Human Hypertension. 2010;25(4):211–217.

Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GY, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais l. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–3104.

Most read articles by the same author(s)

1 2 > >>